A study of 25 patients at our institution with gastroparesis (19 with diabetic gastroparesis) showed that this benefit was sustained at 12 months. [14] Weight gain of up to 8 pounds at 6 months ...

Gastroparesis is a chronic disorder that affects a significant subset of the population. Diabetes mellitus is a risk factor for the development of gastroparesis. Currently, metoclopramide is the ...

McCallum and colleagues studied whether mitemcinal, an orally administered motilin agonist, is effective at improving diabetes-related gastroparesis symptoms. The authors conclude that mitemcinal ...

Medically reviewed by Isabel Casimiro, MD, PhDA gastroparesis diet involves eating smaller meals with foods that are softer ...

Gastroparesis is most commonly associated with diabetes, but is also seen as a complication of other diseases and is also a recognised side effect of GLP-1 agonists used to treat diabetes and for ...

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025. Gimoti remains only approved drug shown to reduce hospitalizations, emergency ...

NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global gastroparesis drugs market size is estimated to grow by USD 1.42 billion from ...

Evoke Pharma (EVOK) underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA’s recent update ...

The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize ...

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company ...